- Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism
[作者：Buller, HR; Prins, MH; Lensing, AWA; Decousus, H; Jacobson, BF; Minar, E; Chlumsky, J; Verhamme, P; Wells, P; Agnelli, G; Cohen, A; Berkowitz, SD; Bounameaux, H; Davidson, BL; Misselwitz, F; Gallus, AS; Raskob, GE; Schellong, S; Segers, A,期刊：New England Journal of Medicine, 页码：1287-1297 , 文章类型： Article，,卷期：2012年366-14]
- BACKGROUND A fixed-dose regimen of rivaroxaban, an oral factor Xa inhibitor, has been shown to be as effective as standard anticoagulant therapy for the treatment of deep-vein thrombosis, without the need for laboratory ...
- The journal's App for the iPad
[作者：Campion, EW; Bowab, CL; Prince, JM; Muenning, JE; Easley, TJ; Drazen, JM,期刊：New England Journal of Medicine, 页码：1342-1342 , 文章类型： Editorial Material，,卷期：2012年366-14]
-
- Pyronaridine-Artesunate versus Mefloquine plus Artesunate for Malaria
[作者：Rueangweerayut, R; Phyo, AP; Uthaisin, C; Poravuth, Y; Binh, TQ; Tinto, H; Penali, LK; Valecha, N; Tien, NT; Abdulla, S; Borghini-Fuhrer, I; Duparc, S; Shin, CS; Fleckenstein, L,期刊：New England Journal of Medicine, 页码：1298-1309 , 文章类型： Article，,卷期：2012年366-14]
- BACKGROUND Pyronaridine-artesunate is an artemisinin-based combination therapy under evaluation for the treatment of Plasmodium falciparum and P. vivax malaria. METHODS We conducted a phase 3, open-label, multicenter, no...
- Suicide and Cardiovascular Death after a Cancer Diagnosis
[作者：Fang, F; Fall, K; Mittleman, MA; Sparen, P; Ye, WM; Adami, HO; Valdimarsdottir, U,期刊：New England Journal of Medicine, 页码：1310-1318 , 文章类型： Article，,卷期：2012年366-14]
- BACKGROUND Receiving a diagnosis of cancer is a traumatic experience that may trigger immediate adverse health consequences beyond the effects of the disease or treatment. METHODS Using Poisson and negative binomial regr...
- Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial
[作者：Haynes, BF; Gilbert, PB; McElrath, MJ; Zolla-Pazner, S; Tomaras, GD; Alam, SM; Evans, DT; Montefiori, DC; Karnasuta, C; Sutthent, R; Liao, HX; DeVico, AL; Lewis, GK; Williams, C; Pinter, A; Fong, Y; Janes, H; DeCamp, A; Huang, YD; Rao, M; Billings, E; Karasavvas, N; Robb, ML; Ngauy, V; de Souza, MS; Paris, R; Ferrari, G; Bailer, RT; Soderberg, KA; Andrews, C; Berman, PW; Frahm, N; De Rosa, SC; Alpert, MD; Yates, NL; Shen, XY; Koup, RA; Pitisuttithum, P; Kaewkungwal, J; Nitayaphan, S; Rerks-Ngarm, S; Michael, NL; Kim, JH,期刊：New England Journal of Medicine, 页码：1275-1286 , 文章类型： Article，,卷期：2012年366-14]
- BACKGROUND In the RV144 trial, the estimated efficacy of a vaccine regimen against human immunodeficiency virus type 1 (HIV-1) was 31.2%. We performed a case-control analysis to identify antibody and cellular immune corr...
|